XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.1
Segment Information and Concentrations (Table) (USD $)
3 Months Ended
Mar. 31, 2019
Segment Information And Concentrations Table  
Schedule of Operating Segment

Segment net revenues, segment operating expenses and segment contribution information consisted of the following for the three months ended March 31, 2019:

 

    For the Three Months Ended March 31, 2019  
    Pharmaceutical     Pharmaceutical        
    Compounding     Drug Development     Total  
Net revenues   $ 12,290     $ -     $ 12,290  
Cost of sales     (3,898 )     -       (3,898 )
Gross profit     8,392       -       8,392  
                         
Operating expenses:                        
Selling, general and administrative     5,715       43       5,758  
Research and development     125       136       261  
Segment contribution     2,552       (179 )     2,373  
Corporate, selling, general and administrative                     2,719  
Research and development                     144  
Amortization of intangible assets                     66  
Operating loss                   $ (556 )